Patents by Inventor Ann Ranger

Ann Ranger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
    Patent number: 11142794
    Abstract: The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a CD40 or CD40L antagonist such as anti-CD40 antibody, anti-CD40L antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 12, 2021
    Assignees: UCB BIOPHARMA SRL, BIOGEN MA INC.
    Inventors: Geoffrey Johnston, Carrie G. Wager, Huo Li, Ann Ranger
  • MOLECULAR SIGNATURES FOR USE IN DIAGNOSIS AND RESPONSE TO TREATMENT ANALYSIS OF AUTOIMMUNE DISEASES
    Publication number: 20180265925
    Abstract: The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a CD40 or CD40L antagonist such as anti-CD40 antibody, anti-CD40L antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment.
    Type: Application
    Filed: October 4, 2016
    Publication date: September 20, 2018
    Inventors: GEOFFREY JOHNSTON, CARRIE G. WAGER, HUO LI, ANN RANGER
  • Regulation of Th2 cell activity by modulation of NFATp and NFAT4 activity
    Publication number: 20060068420
    Abstract: The invention demonstrates that NFATp and NFAT4 are required for the control of lymphocyte homeostasis and act as selective repressors of Th2 cells. The invention provides mice deficient in both NFATp and NFAT4 that exhibit a phenotype characteristic of increased Th2 cell activity. Methods for identifying modulators of Th2 cell activity, using either cells deficient in both NFATp and NFAT4, mice deficient in both NFATp and NFAT4, or indicator compositions containing both NFATp and NFAT4, are provided. Methods of regulating Th2 cell activity using agents that modulate the activity of NFATp and NFAT4 are also provided. Methods for diagnosing disorders associated with aberrant Th2 cell activity, by assessing changes in NFATp and/or NFAT4 expression, are also provided.
    Type: Application
    Filed: July 20, 2005
    Publication date: March 30, 2006
    Applicant: HARVARD UNIVERSITY
    Inventors: Laurie Glimcher, Ann Ranger, Mohamed Oukka